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Background: COVID-19 vaccine development is proceeding at an unprecedented pace. Once COVID-19 vaccines become widely 
available, it will be necessary to maximize public vaccine acceptance and coverage.  
Objective: This research aimed to analyze the predictors of COVID-19 vaccine acceptance in Russia. 
Methods: A cross-sectional online survey was conducted among Russian adults from September 26
th
 to November 9
th
, 2020. Predictors 
of the intent to take up COVID-19 vaccination were explored using logistic regression.  
Results: Out of 876 participants, 365 (41.7%) would be willing to receive the vaccine if it became available. Acceptance increased for a 
vaccine with verified safety and effectiveness (63.2%). Intention to receive the COVID-19 vaccine was relatively higher among males 
(aOR=2.37, 95% CI 1.41-4.00), people with lower monthly income (aOR=2.94, 95%CI 1.32-6.57), and with positive trust in the 
healthcare system (aOR=2.73, 95% CI 1.76-4.24). The Russian people were more likely to accept the COVID-19 vaccine if they believed 
that the vaccine reduces the risk of virus infection (aOR=8.80, 95%CI 5.21-14.87) or relieves the complications of the disease 
(aOR=10.46, 95%CI 6.09-17.96). Other barriers such as being unconcerned about side-effects (aOR=1.65, 95%CI 1.03-2.65) and the 
effectiveness and safety of the vaccination (aOR=2.55, 95%CI 1.60-4.08), also affected acceptance. 
Conclusions: The study showed the usefulness of the health belief model constructs in understanding the COVID-19 vaccination 
acceptance rate in the Russian population. This rate was influenced by sociodemographic and health-related characteristics, and 
health beliefs. These findings might help guide future efforts for policymakers and stakeholders to improve vaccination rates by 
enhancing trust in the healthcare system. 
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INTRODUCTION 
The COVID-19 (coronavirus) pandemic, originating in 
Wuhan, China, has become a major threat in almost every 
country in the world.1-4 Many strategies to combat 
community spread have frozen almost every country’s 
social and economic activities.5-7 Vaccination is the best 
approach to lessen this dire situation. Worldwide, over 160 
candidate COVID-19 vaccines are under development, with 
over 93 currently in clinical trials (42 in phase I, 30 in phase 
II, and 21 in phase III), as of March 2021.8-11 Furthermore, 
following the first approved COVID-19 mRNA-based 
vaccine, named Comirnaty (Pfizer and BioNTech), in 
December 11th, 2020, for emergency use authorization in 
the USA, a total of 6 vaccines have been authorized for 
early and limited use, and 6 have been approved for full 
use, as of March 2021.10,11 These vaccines exhibit various 
efficacies, for instance, Comirnaty and mRNA-1273 
(Moderna, USA) yield the highest efficacies of 95% and 
94.5%, respectively; Convidecia (CanSinoBIO, China) has a 
moderate efficacy of 65.28%; and CoronaVac (Sinovac, 
China) provides an efficacy of as low as 50.38% in following 
a Brazilian trial.10-14 Specifically, in Russia, 3 vaccines have 
been approved (as of March 2021), including Sputnik V 
(Gamaleya Research Institute, efficacy of 91.6%), 
EpiVacCorona (Vektor State Research Center of Virology 
and Biotechnology in Russia), and CoviVac (Chumakov 
Center at the Russian Academy of Sciences).10 Notably, all 
three of these vaccines have been approved by the Russian 
government for early use, with inadequate data on phase 
III clinical trials.14-16 By March 2021, only the Sputnik V 
phase III efficacy has been announced in February 2nd, 2021 
(91.6%), with the efficacies of the other two vaccines still 
unknown.10 Furthermore, the rapid spread of COVID-19 in 
Russia has been increasing, with a total of more than 4 
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million cases, and over 8,000 new cases each day, as of 
March 2021.17 Thus, to appropriately develop vaccination 
programs, ensure equitable vaccine allocation, and 
understand individuals’ willingness to be vaccinated, 
especially in a country with a large and diverse population 
density such as Russia, it is important to explore the public 
acceptability of COVID-19 vaccines.  
People typically prefer a highly effective vaccine (i.e., more 
than 50% effectiveness), yet this characteristic may make 
the vaccine more expensive.18 Perceptions around the 
safety of the vaccine and sociodemographic characteristics 
also influence acceptance rates. For instance, if a vaccine is 
demonstrated to be safe and effective, people are more 
likely to accept it.19 Males are more likely to accept COVID-
19 vaccines than females.20 Moreover, the health belief 
model, composing of three main constructs: the perceived 
benefits (an individual’s beliefs around vaccination), the 
perceived barriers (the belief that access to vaccination is 
restricted based on social, environmental, and economic 
factors), and cues to action (stimuli that motivate an 
individual to get vaccinated), is one of the most commonly 
used theories in health and illness behavior studies. This 
model has been demonstrated as an important predictor of 
intent to receive COVID-19 vaccines.21 Thus, a series of 
different factors related to sociodemographic and health-
related characteristics, and health beliefs related to COVID-
19 has been compiled for the purpose of investigating the 
association of each factor with the individual’s intention to 
receive the COVID-19 vaccine. Many such studies have 
been conducted in the United States, Saudi Arabia, Chile, 
Indonesia, Malaysia, and Australia.
5,20,22-25
 In Russia, a 
report on vaccine acceptance by Lazarus et al., showed that 
the acceptance rate within the Russian population was 
55%; the lowest of the 19 countries surveyed.19 However, 
for Russian people, the specific details of factors influencing 
COVID-19 vaccine acceptance rates were not provided, only 
the general characteristics were reported. Moreover, an 
assessment of the influence of factors such as health-
related characteristics and health beliefs around COVID-19 
on acceptance rates was not included in the study. 
Therefore, this study has proposed a hypothetical research 
question regarding the intention to receive a vaccine if it 
were to become available, using a similar design to 
previous studies.5, 20,22-25 As the success of any COVID-19 
vaccination program depends greatly on public willingness 
to be vaccinated, this research aimed to analyze the 
predictors of COVID-19 vaccine acceptance in Russia. 
 
METHODS 
Study design and setting 
We conducted a descriptive cross-sectional survey using an 
online questionnaire between September 26th and 
November 9th, 2020. Adults of 18 years old or older and 
currently living in Russia were eligible for inclusion in the 
study. 
A snowball sampling method was used for participant 
recruitment. Briefly, using Microsoft Teams, a study 
invitation including a link to the Google Forms-based 
questionnaire was sent out to lecturers and 1st to 5th year 
students in the Faculty of Medicine, Russian People’s 
Friendship University (RUDN University). Following 
completion of the survey, participants were asked to 
forward the invitations to their friends and colleagues at 
other pharmacies, hospitals, and universities. In addition, 
they were also asked to share the study invitation to their 
email contacts and social networks, including VK 
(VKontakte – a Russian online social media), WhatsApp, 
and Facebook. 
The sample size was calculated using the formula 
N=Z2.p(1−p)/e2, in which Z=2.576 using a confidence level 
of 99%, a margin of error of 0.05, and p=38%, following the 
procedure conducted previously in a similar survey in 
Russia.26 Accordingly, the minimum number of participants 
required in the present study was calculated to be 626. The 
number of participants’ responses was checked after every 
two weeks. Once the number of responses was greater 
than 626, the survey would be closed. 
Questionnaire development and content 
The original questionnaire was formulated in English, based 
on adapting questionnaire tools used in similar studies, 
with new factors added.5, 20,22-25 The questionnaire was 
then translated into Russian by a language expert. To 
ensure face validity of the questionnaire’s content, three 
independent experienced pharmacy experts working in the 
Department of Management and Economics of Pharmacy, 
RUDN University were selected to perform the evaluation, 
correction, and clarification of the questionnaire. 
Additionally, a pilot study was carried out on 30 students 
prior to the main study. To this end, all questions were 
clear and easy to understand, and no changes were made. 
The questionnaire was self-administered and comprised 
three parts (Online appendix). 
 Part 1 - Willingness to receive a COVID-19 vaccine: The 
survey evaluated participant intentions to undergo 
vaccination using a one-item question, ‘If a vaccine 
against COVID-19 infection is available in the market, 
would you take it?’.21,22,27 There were three response 
options including ‘Yes’, ‘No’, and ‘Not sure’. To address 
the primary outcome, these responses were 
dichotomized into ‘Yes’ and ‘No’ (No, Not sure). 
 Part 2 - Health belief: This section was designed to 
measure the participant’s health belief related to 
COVID-19 vaccination.24,28 A total of 17 items were 
used to assess the perceived benefits of a COVID-19 
vaccine (3 questions), perceived barriers to vaccine 
uptake (10 questions), and cues to action (4 questions). 
Each item offered two simplified response options; 
‘Agree’ and ‘Disagree’ because the study was in a form 
of self-administered online survey.24 Several new items 
were also added to this section, including ‘I would only 
take the COVID-19 vaccine if mandatory vaccination is 
required at the workplace’, ‘I would agree to be 
vaccinated against COVID-19 only if it was 
recommended by a trusted doctor’, and ‘The vaccine 
will help to provide long-term immunity’. 
 Part 3 - Sociodemographic and health-related 
characteristics: Participant sociodemographic variables 
were collected, such as gender, marital status, 
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education, urbanicity of environment, occupation, 
average monthly household income, and whether or 
not they were in a healthcare-related job. Participants 
were also asked to answer questions related to their 
health and lifestyle, including smoking status (never 
smoke, former smoker, and current smoker), chronic 
diseases, whether their job required interaction with 
lots of people, whether they had received a positive 
COVID-19 test result, and their trust in the healthcare 
system. For each of these items, two response options 
were given to the participant, ‘Yes’ and ‘No’. For 
health-related items, risk perception was measured 
using a self-assessment single-answer multiple-choice 
scale between 0% and 100%, in increments of 10%, 
with a higher value reflecting a higher perceived risk of 
contracting COVID-19.5 This variable was then grouped 
into the categories 0%, 10-20%, 30-40%, 50-60%, and 
>60%, following the procedure of Harapan et al.5 
Ethical considerations 
Study procedures complied with the principle of the 
Declaration of Helsinki, 1995 (revised in 2013). The Ethics 
Council in Medical Research of the RUDN university 
approved the study protocol (reference: 2608). Data 
collected did not contain any personally-identifiable 
information or protected health information. Participants 
were informed that their participation was completely 
voluntary, with no financial compensation. 
Statistical analysis 
Descriptive statistics were used to determine the frequency 
(n) and percentage (%) of categorical variables. Predictors 
of COVID-19 vaccine acceptance were assessed in a two-
stage process. Firstly, a binary logistic regression was 
performed to explore the associations between each 
individual explanatory variable, i.e., sociodemographic and 
health-related characteristics, and health belief variables, 
and response acceptance (willingness to receive a COVID-
19 vaccine). All variables exhibiting a p-value<0.25 were 
then included in an adjusted analysis in the second analysis 
stage. Each independent variable was attributed an odds 
ratios (OR) with 95% confidence intervals (95%CI), and 
significance (p). Statistical significance was considered at 
p<0.05. All analyses were performed using SPSS 20.0. 
 
RESULTS  
A total of 876 responses were received between 
September 26th and November 9th, 2020. Table 1 presents 
the participant sociodemographic and health-related 
characteristics. A large proportion of participants were 
female (74.3%), with the highest education level being a 
university degree (63.6%). A large number of respondents 
lived in urban areas (87.2%). Regarding health status, most 
respondents had no chronic diseases (69.5%) and had 
never smoked (71.1%). Only 8.6% of people reported that 
they had been infected with COVID-19. Many participants 
(25.3%) believed that they had a 30-40% risk of getting 
COVID-19, whereas only 12.4% and 20.8% said they had 
either 0% chance or more than 60% chance of infection, 
respectively. 
Figure 1 shows the proportion of responses in agreement 
to the health belief model construct. Less than 40% of 
participants believed that vaccination would help reduce 
the risk of virus infection (27.6%), ease the complications 
resulting from the disease (28.8%), and help provide long-
term immunity (37.9%). The most frequently cited barriers 
were the concern about the vaccine’s effectiveness, safety 
(61.5%) and side effects (59.8%). The majority of 
participants stated that their motivation to receive the 
Table 1. Participant characteristics (n=876) 
Variable n (%)* 
Gender  
Female 651 (74.3) 
Male 225 (25.7) 
Age (years)  
18-25 350 (40.0) 
26-40 283 (32.4) 
41-60 177 (20.3) 
>60 64 (7.3) 
Marital status  
Single 483 (55.1) 
Married  393 (44.9) 
Education  
Secondary and lower 184 (21.0) 
Vocationalization 135 (15.4) 




Suburban/Rural 106 (12.1) 




Never smoke 623 (71.1) 
Former smoker 80 (9.1) 
Current smoker 162 (18.5) 
Diagnosed with chronic diseases
‡
  
No 609 (69.5) 




Retired/Housewife/ Student 446 (51.0) 
General worker 290 (33.1) 




No 519 (59.2) 
Yes 354 (40.4) 
Job requiring interaction with lots of 
people 
 
No 474 (54.1) 
Yes 402 (45.9) 
Positive COVID-19 status  
No 765 (87.3) 
Yes 75 (8.6) 
Monthly income (1 thousand RUB)
 ††
  
<20 272 (31.1) 
20-40 235 (26.8) 
41-80 187 (21.3) 
>80 68 (7.8) 
Trust in the healthcare system  
No 464 (53.0) 
Yes 392 (44.7) 
Risk Perception Score (%)  
0 109 (12.4) 
10-20 133 (15.2) 
30-40 222 (25.3) 
50-60 194 (22.1) 
>60 182 (20.8) 
†
 Data were missing for < 1% of participants. 
‡
 Data were missing for < 2% of participants. 
††
 Data were missing for 11.3% of participants 
*
 Percentages may not total 100 owing to rounding and missing 
data. 
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COVID-19 vaccine depended on the availability of sufficient 
reliable information about the safety and effectiveness of 
the vaccine (63.2%). Conversely, factors such as ‘the 
vaccine has been taken by many of the population’ (24.7%), 
‘the vaccine was recommended by a trusted doctor’ 
(19.9%), and ‘mandatory vaccination is required at the 
workplace’ (12.7%) were not reported as impacting their 
decision. 
Out of a total of 876 participants, 365 (41.7%) said they 
would be willing to get the vaccine if it became available. 
Acceptance increased when the vaccine was stated to have 
been proven safe and effective (63.2%). Table 2 shows the 
predictors associated with the intent to receive the vaccine. 
The results indicated that males (aOR=2.37, 95%CI 1.41-
4.00), respondents with a lower monthly income 
(aOR=2.94, 95%CI 1.32-6.57), and those with positive trust 
in the healthcare system (aOR=2.73, 95%CI 1.76-4.24) were 
more likely to be willing to receive the COVID-19 vaccine. 
Respondents who perceived there to be positive benefits of 
the vaccine were more likely to hold an intention to receive 
the vaccine. Individuals who believed that ‘vaccination 
helps reduce the risk of virus infection’ (aOR=8.80, 95%CI 
5.21-14.87), ‘vaccination will ease complications of the 
disease’ (aOR=10.46, 95%CI 6.09-17.96), and ‘the vaccine 
will help to provide long-term immunity’ (aOR=2.73, 95% CI 
1.72-4.35) were more likely to be willing to receive the 
vaccine. Other factors, such as a lack of concern about 
‘side-effects’ (aOR=1.65, 95%CI 1.03-2.65), ‘the 
effectiveness, safety of vaccination’ (aOR=2.55, 95%CI 1.60-
4.08), ‘exaggerating the threat of COVID-19’ (aOR=2.33, 
95%CI 1.05-5.16), ‘fear of injections’ (aOR=2.66, 95% CI 
0.87-8.19), and not having a belief in ‘natural or traditional 
remedies’ (aOR=7.29, 95%CI 1.88-28.30) were also 
associated with a greater willingness to receive the vaccine. 
Lastly, those who reported a need for having the ‘verified 
safety and effectiveness’ (aOR=1.80, 95%CI 1.08-3.00) and 
acknowledging that ‘vaccines were taken by many of the 
population’ (aOR=1.85, 95%CI 1.12-3.08) were nearly twice 
as likely to accept the vaccine as other groups. 
 
DISCUSSION 
Vaccination is an important and effective foundation of 
preventive healthcare. This study found evidence for a 
moderate vaccine acceptance rate of 41.7% if a vaccine 
were to be made available. This rate is comparatively low 
compared with other studies (ranging from 64.7% to 
90.6%).22,23 Our results were broadly in agreement with a 
Statista report, which showed that if the Sputnik V COVID-
19 vaccine became free, and uptake was voluntary, 38.0% 
of Russians would accept it.26 Moreover, if the vaccine were 
proven safe and effective, this acceptance rate significantly 
increased to 63.2%. This somewhat moderate figure was in 
line with the findings of Lazarus et al. (reporting a 54.9% 
Figure 1. Proportion of respondents agreeing with health belief model constructs (N = 876) 
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acceptance rate) following a study conducted in Russia, 
with a similar hypothetical setting to the present study.19 If 
these figures are reflective of the entire population, this 
could represent a challenge for policymakers to achieve 
widespread vaccine coverage. The approach to ensuring 
the effectiveness of a future vaccine program must be 
comprehensive and must take into account determinants 
that relate not only to vaccine safety and effectiveness, but 
also to factors around individual capability, individual 
motivation, and opportunity.29 
Analysis of participant demographic characteristics 
revealed that nearly half of the respondents (45.9%) were 
occupied in a job requiring interaction with many people. 
Although social interaction has been shown to be one of 
the most important risk factors of COVID-19 infection, the 
majority of participants (25.3%) had a low perception of 
their own infection risk (score of 30-40%).30 Therefore, 
raising awareness around the risk of contracting COVID-19 
is essential for the Russian population. Risk perception 
plays a crucial role in shaping health-related behaviors in a 
Table 2. Unadjusted and adjusted logistic regression analyses of factors associated with the acceptance of a COVID-19 vaccine among 
respondents in Russia (n = 876) 





OR (95%CI) p-value aOR (95%CI) p-value 
Gender       
Female  651 (74.3) 240 (36.9) 1  1  
Male 225 (25.7) 125 (55.6) 2.14 (1.57-2.91) <0.001 2.37 (1.41-4.00) 0.001 
Age (years)       
18-25 350 (40.0) 134 (38.3) 1  1  
26-40 283 (32.4) 114 (40.3) 1.09 (0.79-1.50) 0.609 2.01 (0.57-7.11) 0.277 
41-60 177 (20.3) 84 (47.5) 1.46 (1.01-2.10) 0.044 2.44 (0.70-8.46) 0.161 
>60 64 (7.3) 32 (50) 1.61 (0.94-2.75) 0.080 1.39 (0.53-3.60) 0.503 
Marital status       
Single 483 (55.1) 199 (41.2) 1    
Married  393 (44.9) 166 (42.2) 1.04 (0.80-1.37) 0.757   
Education       
Secondary and lower 184 (21.0) 81 (44) 1    
Vocationalization 135 (15.4) 59 (43.7) 0.99 (0.63-1.55) 0.955   
University 557 (63.6) 225 (40.4) 0.86 (0.62-1.20) 0.387   
Urbanicity       
Suburban/Rural 106 (12.1) 49 (46.2) 1    
Urban  764 (87.2) 314 (41.1) 0.81 (0.54-1.22) 0.316   
Smoking status       
Never smoke 623 (71.1) 250 (40.1) 1  1  
Former smoker 80 (9.1) 34 (42.5) 1.10 (0.69-1.77) 0.684 0.70 (0.30-1.62) 0.408 
Current smoker 162 (18.5) 76 (46.9) 1.32 (0.93- 1.87) 0.119 1.46 (0.83-2.58) 0.194 
Diagnosed with chronic diseases       
No 609 (69.5) 255 (41.9) 1    
Yes 252 (28.8) 105 (41.7) 0.99 (0.74-1.34) 0.956   
Occupation category       
Retired/Housewife/Student 446 (51.0) 177 (83.1) 1  1  
General worker 290 (33.1) 124 (42.8) 1.14 (0.84-1.53) 0.408 0.57 (0.17-1.90) 0.363 
Managerial 139 (15.9) 63 (45.3) 1.26 (0.86-1.85) 0.239 0.75 (0.22-2.58) 0.652 
Healthcare related job       
No 519 (59.2) 234 (45.1) 1  1  
Yes 354 (40.4) 129 (36.4) 0.70 (0.53-0.92) 0.011 0.73 (0.44-1.21) 0.221 
Job requiring interaction with lots of 
people 
      
No 474 (54.1) 192 (40.5) 1    
Yes 402 (45.9) 173 (43) 1.11 (0.85-1.45) 0.449   
Positive COVID-19 status       
No 765 (87.3) 333 (43.5) 1  1  
Yes 75 (8.6) 27 (36) 0.73 (0.45-1.19) 0.210 0.65 (0.24-1.75) 0.394 
Monthly income (1 thousand RUB)       
<20 272 (31.1) 123 (45.2) 1.73 (0.99-3.03) 0.057 2.34 (1.05-5.25) 0.038 
20-40 235 (26.8) 105 (44.7) 1.69 (0.96-2.99) 0.071 2.94 (1.32-6.57) 0.008 
41-80 187 (21.3) 79 (42.2) 1.53 (0.85-2.75) 0.155 2.44 (1.08-5.51) 0.032 
>80 68 (7.8) 22 (32.4) 1  1  
Trust in the healthcare system       
No 464 (53.0) 143 (30.8) 1  1  
Yes 392 (44.7) 218 (55.6) 2.81 (2.13-3.72) <0.001 2.73 (1.76-4.24) <0.001 
Risk Perception Score (%)       
0 109 (12.4) 46 (42.2) 1  1  
10-20 133 (15.2) 54 (40.6) 0.94 (0.56-1.57) 0.801 0.73 (0.33-1.65) 0.452 
30-40 222 (25.3) 111 (50) 1.37 (0.86-2.17) 0.182 1.18 (0.56-2.48) 0.654 
50-60 194 (22.1) 82 (42.3) 1.00 (0.62-1.61) 0.991 0.67 (0.32-1.42) 0.300 
>60 182 (20.8) 67 (36.8) 0.80 (0.49-1.30) 0.362 0.67 (0.27-1.65) 0.383 
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variety of settings involving the control of infectious 
diseases.29 A person with a higher risk perception will 
perform more effective preventive actions, thus preventing 
spread of the virus. To this end, a suggestion for 
policymakers might be the utilization of the mass media, 
especially social media networks, to facilitate awareness.31 
The design of risk messages, the source of the message 
(credibility and trust), and the target of the message (at-risk 
populations) should be considered the most critical factors 
in increasing risk awareness in a community.32 
Additionally, more than half of the participants (53%) 
reported a lack of trust in the healthcare system. Previous 
studies have found that participants with higher levels of 
confidence in the healthcare system are more likely to 
accept a vaccine, in agreement with the current study 
(aOR=2.73, 95%CI 1.76-4.24).22 Furthermore, a small 
Table 2 (cont.). Unadjusted and adjusted logistic regression analyses of factors associated with the acceptance of a COVID-19 vaccine 
among respondents in Russia (n = 876) 





OR (95% CI) p-value aOR (95% CI) p-value 
Perceived benefits 
Vaccination helps reduce the risk of virus infection 
Disagree 634 (72.4) 171 (27) 1  1  
Agree 242 (27.6) 194 (80.2) 10.94 (7.62-15.71) <0.001 8.80 (5.21-14.87) <0.001 
Vaccination will ease complications of the disease 
Disagree 624 (71.2) 170 (27.2) 1  1  
Agree 252 (28.8) 195 (77.4) 9.14 (6.48-12.88) <0.001 10.46 (6.09-17.96) <0.001 
The vaccine will help to provide long-term immunity 
Disagree 544 (62.1) 175 (32.2) 1  1  
Agree 332 (37.9) 190 (57.2) 2.82 (2.13-3.74) <0.001 2.73 (1.72-4.35) <0.001 
Perceived barriers 
Concern about possible side effects of vaccination 
Disagree 352 (40.2) 178 (50.6) 1.84 (1.40-2.43) <0.001 1.65 (1.03-2.65) 0.036 
Agree 524 (59.8) 187 (35.7) 1  1  
Unproven vaccine safety and effectiveness 
Disagree 337 (38.5) 193 (57.3) 2.86 (2.16-3.79) <0.001 2.55 (1.60-4.08) <0.001 
Agree 539 (61.5) 172 (31.9) 1  1  
Concern of affordability (high cost) 
Disagree 688 (78.5) 282 (41) 1    
Agree 188 (21.5) 83 (44.1) 1.14 (0.82-1.58) 0.436   
Religious reasons 
Disagree 854 (97.5) 353 (41.3) 1  1  
Agree 22 (2.5) 12 (54.5) 1.70 (0.73-3.99) 0.220 8.08 (1.52-42.93) 0.014 
The threat of COVID-19 has been exaggerated 
Disagree 761 (86.9) 336 (44.2) 2.35 (1.50-3.66) <0.001 2.33 (1.05-5.16) 0.038 
Agree 115 (13.1) 29 (25.2) 1  1  
Afraid of injections 
Disagree 833 (95.1) 356 (42.7) 2.82 (1.34-5.95) 0.007 2.66 (0.87-8.19) 0.088 
Agree 43 (4.9) 9 (20.9) 1  1  
Belief in natural or traditional remedies 
Disagree 833 (95.1) 352 (42.3) 1.69 (0.87-3.28) 0.123 7.29 (1.88-28.30) 0.004 
Agree 43 (4.9) 13 (30.2) 1  1  
I’m young and healthy 
Disagree 783 (89.4) 333 (42.5) 1.41 (0.90-2.21) 0.135 3.60 (1.41-9.18) 0.007 
Agree 93 (10.6) 32 (34.4) 1  1  
I don’t need the vaccine because I do all the right things (hand washing and wearing masks, gloves) 
Disagree 710 (81.1) 303 (42.7) 1.25 (0.88-1.77) 0.211 1.23 (0.67-2.24) 0.507 
Agree 166 (18.9) 62 (37.3) 1  1  
The best way is to let nature take its course 
Disagree 738 (84.2) 329 (44.6) 2.28 (1.52-3.42) <0.001 2.57 (1.24-5.34) 0.011 
Agree 138 (15.8) 36 (26.1) 1  1  
Cues to action 
Verified safety and effectiveness 
Disagree 322 (36.8) 123 (38.2) 1  1  
Agree 554 (63.2) 242 (43.7) 1.26 (0.95-1.66) 0.113 1.80 (1.08-3.00) 0.025 
Taken by many of the population 
Disagree 660 (75.3) 256 (38.8) 1  1  
Agree 216 (24.7) 109 (50.5) 1.61 (1.18-2.19) 0.003 1.85 (1.12-3.08) 0.017 
Recommended by a trusted doctor 
Disagree 702 (80.1) 273 (38.9) 1  1  
Agree 174 (19.9) 92 (52.9) 1.76 (1.26-2.46) 0.001 1.02 (0.56-1.86) 0.951 
Mandatory vaccination is required at the workplace 
Disagree 765 (87.3) 310 (40.5) 1  1  
Agree 111 (12.7) 55 (49.5) 1.44 (0.97-2.15) 0.072 2.76 (1.37-5.58) 0.005 
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percentage of participants agreed that they would accept 
the vaccine only if recommended to do so by a trusted 
doctor (19.9%), in contradiction to a previous study in 
Americans (59%).33 Therefore, improving healthcare 
services and enhancing community trust is important for 
increasing vaccine acceptance rates.  
Conversely, gender and monthly income were the only two 
demographic predictors of vaccination acceptance, which 
suggests a need for gender- and income-based educational 
interventions. In agreement with the findings of a 
previously published study, male gender was a positive 
predictor for the acceptance of a COVID-19 vaccine.20 This 
result could be due to the reported high rates of COVID-19-
related morbidity and mortality among male COVID-19 
patients.34,35 Another explanation might be that males hold 
more positive perceptions about the effectiveness and 
safety of the vaccine. Regarding income factors, people 
with lower incomes were more willing to accept the 
vaccine than those with higher incomes. This might be 
related to the government and public health authority 
implementing preferential policies for those on low-
incomes, such as providing free COVID-19 vaccinations, yet 
charging households with higher incomes for the same 
services. 
Health belief models, including the perceived benefits and 
barriers, were strongly associated with vaccine acceptance. 
In agreement with the results of other studies related to 
barriers inhibiting vaccination, most participants in this 
study were worried about the effectiveness, safety, and 
side effects of vaccines (nearly 60%).28 Meanwhile, only a 
small proportion of participants (21.5%) viewed 
affordability as a barrier. This reflected the relative 
importance of vaccine efficacy compared to other factors 
such as affordability, in agreement with previous 
research.24 Religious factors, fear of injections, and belief in 
natural or traditional remedies were considered barriers by 
only few participants, in agreement with Neumann-Böhme 
et al.28 The results also showed that individuals who would 
not accept a COVID-19 vaccine were more likely to agree 
that the threat of COVID-19 and the danger of this virus is 
not legitimate and has been exaggerated, similar to the 
findings of Dodd et al.25 Thus, these individuals potentially 
underestimated the seriousness of the risk posed by the 
coronavirus to them or their community, or that they might 
believe the virus to only affect people over a certain age or 
the immunosuppressed.36 Overall, to motivate people to 
receive the vaccines, scientific evidence on the vaccine 
efficacy, safety, and side effects must be made available to 
the public. Using health technology interventions including 
telephone reminders, text message reminders, and 
smartphone applications may contribute to achieving a 
positive vaccination behavior change, and therefore, may 
help improve vaccination rates and consequently public 
health.37 As education, information, and communication 
have been demonstrated to improve the willingness to 
receive vaccinations (e.g., for respiratory viruses), it is 
important that the government implements credible 
measures, and informs and educates the Russian 
population on the impact of the COVID-19 contagion.38 
Limitation and future perspectives 
This study depicts a snapshot of the intentions of 
participants in a hypothetical situation where a vaccine is 
made available. In the future, when the vaccine does 
become available, participants’ intentions may be different 
to those captured here. Future studies are needed with the 
scope of focusing on these and similar issues in a real-life 
setting where vaccines are popularized, and observe how 
public intentions change over time. Another limitation was 
that a snowball sampling strategy may not accurately 
reflect a cross-section of the research population. The 
online survey was distributed solely using social media and 
email, and thus may have been biased towards recruiting a 
sample with higher educational attainment and literacy. 
Lastly, the variation in internet access across different 
regions of the country may have added to the selection 
bias, as the quality of internet access varies across the 
population. Nevertheless, this sampling method was 
considered the most appropriate for rapidly capturing a 




This work focused on COVID-19 vaccine acceptance rates in 
Russia, taking into account the relationships with 
sociodemographic and health-related characteristics, and 
health beliefs. In a sample of 876 people, 41.7% 
respondents were willing to receive the COVID-19 vaccine. 
This rate increased to 63.2% if the vaccine were proven to 
be safe and effective. Gender and income significantly 
influenced the acceptance rates. We conclude that 
policymakers and stakeholders in various sectors of the 
population need to strive to improve vaccination rates. In 
addition, the government should introduce an evidence-
based community messaging strategy, together with an 
education program focusing on the threat of virus, the 
benefits of vaccination, assessment of efficacy, and any 
side effects. Lastly, since intent to be vaccinated was 
associated with trust in the healthcare system, it is also 
important to increase the quality of services provided in 
the medical sector. 
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